CA2499123A1 - Ii-key/antigenic epitope hybrid peptide vaccines - Google Patents

Info

Publication number

CA2499123A1

CA2499123A1 CA002499123A CA2499123A CA2499123A1 CA 2499123 A1 CA2499123 A1 CA 2499123A1 CA 002499123 A CA002499123 A CA 002499123A CA 2499123 A CA2499123 A CA 2499123A CA 2499123 A1 CA2499123 A1 CA 2499123A1

Authority

CA

Canada

Prior art keywords

mhc class

epitope

presented

amino acid

peptide

Prior art date

2002-09-17

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 230000000890 antigenic effect Effects 0.000 title claims abstract description 306
• 108010028930 invariant chain Proteins 0.000 title claims description 312
• 229940023041 peptide vaccine Drugs 0.000 title description 11
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 659
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 240
• 108091054438 MHC class II family Proteins 0.000 claims abstract description 143
• 230000002708 enhancing effect Effects 0.000 claims abstract description 112
• 102000043131 MHC class II family Human genes 0.000 claims abstract description 111
• 229920001184 polypeptide Polymers 0.000 claims abstract description 79
• 230000030741 antigen processing and presentation Effects 0.000 claims abstract description 57
• 239000000126 substance Substances 0.000 claims abstract description 44
• 125000000539 amino acid group Chemical group 0.000 claims abstract description 33
• 150000001413 amino acids Chemical class 0.000 claims description 210
• 229940024606 amino acid Drugs 0.000 claims description 209
• 108090000623 proteins and genes Proteins 0.000 claims description 154
• 102000004169 proteins and genes Human genes 0.000 claims description 126
• 238000000034 method Methods 0.000 claims description 125
• 210000004027 cell Anatomy 0.000 claims description 121
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 88
• 102000043129 MHC class I family Human genes 0.000 claims description 67
• 108091054437 MHC class I family Proteins 0.000 claims description 65
• 230000004044 response Effects 0.000 claims description 57
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 55
• 210000004899 c-terminal region Anatomy 0.000 claims description 51
• 230000028993 immune response Effects 0.000 claims description 51
• 230000004048 modification Effects 0.000 claims description 50
• 238000012986 modification Methods 0.000 claims description 50
• 150000007523 nucleic acids Chemical group 0.000 claims description 47
• 229960005486 vaccine Drugs 0.000 claims description 35
• 241000700605 Viruses Species 0.000 claims description 31
• 230000014509 gene expression Effects 0.000 claims description 31
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 29
• 238000012217 deletion Methods 0.000 claims description 29
• 230000037430 deletion Effects 0.000 claims description 29
• 238000006467 substitution reaction Methods 0.000 claims description 26
• 210000000612 antigen-presenting cell Anatomy 0.000 claims description 25
• 241000282414 Homo sapiens Species 0.000 claims description 24
• 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims description 23
• 230000003053 immunization Effects 0.000 claims description 23
• 239000000203 mixture Substances 0.000 claims description 22
• 230000001717 pathogenic effect Effects 0.000 claims description 20
• 244000052769 pathogen Species 0.000 claims description 19
• 208000015181 infectious disease Diseases 0.000 claims description 18
• 125000001151 peptidyl group Chemical group 0.000 claims description 18
• 239000000816 peptidomimetic Substances 0.000 claims description 17
• 239000000470 constituent Substances 0.000 claims description 14
• 102000039446 nucleic acids Human genes 0.000 claims description 14
• 108020004707 nucleic acids Proteins 0.000 claims description 14
• 238000002560 therapeutic procedure Methods 0.000 claims description 13
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 12
• 102000004127 Cytokines Human genes 0.000 claims description 11
• 108090000695 Cytokines Proteins 0.000 claims description 11
• 241000124008 Mammalia Species 0.000 claims description 11
• 230000002458 infectious effect Effects 0.000 claims description 11
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 10
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 10
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 9
• 241000700618 Vaccinia virus Species 0.000 claims description 8
• 230000007423 decrease Effects 0.000 claims description 8
• 230000001965 increasing effect Effects 0.000 claims description 8
• 230000007935 neutral effect Effects 0.000 claims description 8
• 230000001105 regulatory effect Effects 0.000 claims description 8
• 230000035945 sensitivity Effects 0.000 claims description 8
• 230000001900 immune effect Effects 0.000 claims description 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
• 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 5
• 206010022000 influenza Diseases 0.000 claims description 5
• 108020004999 messenger RNA Proteins 0.000 claims description 5
• 230000001575 pathological effect Effects 0.000 claims description 5
• 241000193738 Bacillus anthracis Species 0.000 claims description 4
• 108020004511 Recombinant DNA Proteins 0.000 claims description 4
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 3
• 238000011534 incubation Methods 0.000 claims description 3
• 239000004475 Arginine Substances 0.000 claims description 2
• 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims description 2
• 101710170470 Glycoprotein 42 Proteins 0.000 claims description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
• 239000004472 Lysine Substances 0.000 claims description 2
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
• 229960003121 arginine Drugs 0.000 claims description 2
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
• 229960003104 ornithine Drugs 0.000 claims description 2
• 230000004962 physiological condition Effects 0.000 claims description 2
• 230000002441 reversible effect Effects 0.000 claims description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 3
• 229940009098 aspartate Drugs 0.000 claims 3
• 229930195712 glutamate Natural products 0.000 claims 3
• RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 2
• 230000010261 cell growth Effects 0.000 claims 2
• 238000011144 upstream manufacturing Methods 0.000 claims 2
• ZNJCNZUENFLSJJ-QMMMGPOBSA-N (2s)-2-(diiodoamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N(I)I)CC1=CC=C(O)C=C1 ZNJCNZUENFLSJJ-QMMMGPOBSA-N 0.000 claims 1
• BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 claims 1
• XWHHYOYVRVGJJY-UHFFFAOYSA-N 4-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-UHFFFAOYSA-N 0.000 claims 1
• GTVVZTAFGPQSPC-UHFFFAOYSA-N 4-nitrophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-UHFFFAOYSA-N 0.000 claims 1
• NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 claims 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 1
• 108060003951 Immunoglobulin Proteins 0.000 claims 1
• QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
• QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
• 229960002173 citrulline Drugs 0.000 claims 1
• 230000000295 complement effect Effects 0.000 claims 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
• 102000018358 immunoglobulin Human genes 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 229960000310 isoleucine Drugs 0.000 claims 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
• 229930182817 methionine Natural products 0.000 claims 1
• XJODGRWDFZVTKW-ZCFIWIBFSA-N n-methylleucine Chemical compound CN[C@@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-ZCFIWIBFSA-N 0.000 claims 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
• 239000004474 valine Substances 0.000 claims 1
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 298
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 298
• 235000001014 amino acid Nutrition 0.000 description 188
• 235000018102 proteins Nutrition 0.000 description 105
• 125000003275 alpha amino acid group Chemical group 0.000 description 92
• 108091007433 antigens Proteins 0.000 description 76
• 102000036639 antigens Human genes 0.000 description 76
• 206010028980 Neoplasm Diseases 0.000 description 75
• 239000000427 antigen Substances 0.000 description 75
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 62
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 61
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 54
• 102100038358 Prostate-specific antigen Human genes 0.000 description 53
• 239000013566 allergen Substances 0.000 description 50
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 45
• 201000011510 cancer Diseases 0.000 description 42
• 108700028369 Alleles Proteins 0.000 description 38
• 230000001225 therapeutic effect Effects 0.000 description 37
• 201000010099 disease Diseases 0.000 description 35
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
• 108020004414 DNA Proteins 0.000 description 34
• 208000026935 allergic disease Diseases 0.000 description 34
• 150000001875 compounds Chemical class 0.000 description 33
• 206010020751 Hypersensitivity Diseases 0.000 description 30
• 102000003425 Tyrosinase Human genes 0.000 description 30
• 108060008724 Tyrosinase Proteins 0.000 description 30
• 201000001441 melanoma Diseases 0.000 description 30
• 230000007815 allergy Effects 0.000 description 28
• 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 27
• 210000004443 dendritic cell Anatomy 0.000 description 27
• 230000000694 effects Effects 0.000 description 26
• 238000002255 vaccination Methods 0.000 description 23
• 230000006870 function Effects 0.000 description 22
• 239000013598 vector Substances 0.000 description 22
• 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 21
• 230000005867 T cell response Effects 0.000 description 21
• 229960004784 allergens Drugs 0.000 description 21
• 125000006850 spacer group Chemical group 0.000 description 21
• 108010058597 HLA-DR Antigens Proteins 0.000 description 20
• 102000006354 HLA-DR Antigens Human genes 0.000 description 20
• 102100031413 L-dopachrome tautomerase Human genes 0.000 description 19
• 238000011282 treatment Methods 0.000 description 19
• 230000003612 virological effect Effects 0.000 description 18
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 17
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 17
• 102100022430 Melanocyte protein PMEL Human genes 0.000 description 16
• 239000003814 drug Substances 0.000 description 16
• 238000002649 immunization Methods 0.000 description 16
• 238000000338 in vitro Methods 0.000 description 16
• 238000003786 synthesis reaction Methods 0.000 description 16
• 101800001271 Surface protein Proteins 0.000 description 15
• 230000015572 biosynthetic process Effects 0.000 description 15
• 230000004957 immunoregulator effect Effects 0.000 description 15
• 230000007246 mechanism Effects 0.000 description 15
• 239000002131 composite material Substances 0.000 description 14
• 229940079593 drug Drugs 0.000 description 14
• 239000002502 liposome Substances 0.000 description 14
• 230000008569 process Effects 0.000 description 14
• 241000282326 Felis catus Species 0.000 description 13
• 208000006673 asthma Diseases 0.000 description 13
• 238000009169 immunotherapy Methods 0.000 description 13
• 238000001727 in vivo Methods 0.000 description 13
• 125000005647 linker group Chemical group 0.000 description 13
• 239000000047 product Substances 0.000 description 13
• LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 12
• 101710093778 L-dopachrome tautomerase Proteins 0.000 description 12
• 238000004519 manufacturing process Methods 0.000 description 12
• 230000001404 mediated effect Effects 0.000 description 12
• 230000037361 pathway Effects 0.000 description 12
• 210000004881 tumor cell Anatomy 0.000 description 12
• 108010041986 DNA Vaccines Proteins 0.000 description 11
• 229940021995 DNA vaccine Drugs 0.000 description 11
• 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 11
• 208000010668 atopic eczema Diseases 0.000 description 11
• 239000002299 complementary DNA Substances 0.000 description 11
• 238000011161 development Methods 0.000 description 11
• -1 polymethylene Polymers 0.000 description 11
• 244000105624 Arachis hypogaea Species 0.000 description 10
• 241001674044 Blattodea Species 0.000 description 10
• 108010074328 Interferon-gamma Proteins 0.000 description 10
• 206010046865 Vaccinia virus infection Diseases 0.000 description 10
• 239000003659 bee venom Substances 0.000 description 10
• 238000013461 design Methods 0.000 description 10
• 210000002443 helper t lymphocyte Anatomy 0.000 description 10
• 238000002347 injection Methods 0.000 description 10
• 239000007924 injection Substances 0.000 description 10
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
• 208000007089 vaccinia Diseases 0.000 description 10
• 108010074032 HLA-A2 Antigen Proteins 0.000 description 9
• 102000025850 HLA-A2 Antigen Human genes 0.000 description 9
• 102100037611 Lysophospholipase Human genes 0.000 description 9
• 108010058864 Phospholipases A2 Proteins 0.000 description 9
• 210000000987 immune system Anatomy 0.000 description 9
• 239000002245 particle Substances 0.000 description 9
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
• 230000010076 replication Effects 0.000 description 9
• 210000001519 tissue Anatomy 0.000 description 9
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 8
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 8
• 102100037850 Interferon gamma Human genes 0.000 description 8
• 241001465754 Metazoa Species 0.000 description 8
• 241000699670 Mus sp. Species 0.000 description 8
• 239000002671 adjuvant Substances 0.000 description 8
• 230000000172 allergic effect Effects 0.000 description 8
• 238000003556 assay Methods 0.000 description 8
• 230000003190 augmentative effect Effects 0.000 description 8
• 238000009472 formulation Methods 0.000 description 8
• 230000002163 immunogen Effects 0.000 description 8
• 230000035772 mutation Effects 0.000 description 8
• 235000020232 peanut Nutrition 0.000 description 8
• 239000013612 plasmid Substances 0.000 description 8
• 238000002360 preparation method Methods 0.000 description 8
• 230000001177 retroviral effect Effects 0.000 description 8
• 235000010777 Arachis hypogaea Nutrition 0.000 description 7
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
• 241000282412 Homo Species 0.000 description 7
• 241000746983 Phleum pratense Species 0.000 description 7
• 108091008874 T cell receptors Proteins 0.000 description 7
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
• 230000004913 activation Effects 0.000 description 7
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 7
• 230000002349 favourable effect Effects 0.000 description 7
• 239000012634 fragment Substances 0.000 description 7
• 210000003491 skin Anatomy 0.000 description 7
• 235000002639 sodium chloride Nutrition 0.000 description 7
• 235000018185 Betula X alpestris Nutrition 0.000 description 6
• 235000018212 Betula X uliginosa Nutrition 0.000 description 6
• 108010070675 Glutathione transferase Proteins 0.000 description 6
• 108010086377 HLA-A3 Antigen Proteins 0.000 description 6
• 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 6
• 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 6
• 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 6
• 108010002350 Interleukin-2 Proteins 0.000 description 6
• 102000000588 Interleukin-2 Human genes 0.000 description 6
• 102000004388 Interleukin-4 Human genes 0.000 description 6
• 108090000978 Interleukin-4 Proteins 0.000 description 6
• 108010010995 MART-1 Antigen Proteins 0.000 description 6
• 102100023123 Mucin-16 Human genes 0.000 description 6
• 206010033128 Ovarian cancer Diseases 0.000 description 6
• 206010061535 Ovarian neoplasm Diseases 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 230000003281 allosteric effect Effects 0.000 description 6
• 125000002091 cationic group Chemical group 0.000 description 6
• 125000003636 chemical group Chemical group 0.000 description 6
• 230000000875 corresponding effect Effects 0.000 description 6
• 108010051081 dopachrome isomerase Proteins 0.000 description 6
• 230000006698 induction Effects 0.000 description 6
• 238000003780 insertion Methods 0.000 description 6
• 230000037431 insertion Effects 0.000 description 6
• 150000002632 lipids Chemical class 0.000 description 6
• 230000003389 potentiating effect Effects 0.000 description 6
• 230000009257 reactivity Effects 0.000 description 6
• 150000003839 salts Chemical class 0.000 description 6
• 241000894007 species Species 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 230000000699 topical effect Effects 0.000 description 6
• 239000003053 toxin Substances 0.000 description 6
• 231100000765 toxin Toxicity 0.000 description 6
• 108700012359 toxins Proteins 0.000 description 6
• 241000701161 unidentified adenovirus Species 0.000 description 6
• 241001430294 unidentified retrovirus Species 0.000 description 6
• 235000017060 Arachis glabrata Nutrition 0.000 description 5
• 235000018262 Arachis monticola Nutrition 0.000 description 5
• 208000035473 Communicable disease Diseases 0.000 description 5
• 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 5
• 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 5
• 108010075704 HLA-A Antigens Proteins 0.000 description 5
• 102000011786 HLA-A Antigens Human genes 0.000 description 5
• 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 5
• 108010035452 HLA-A1 Antigen Proteins 0.000 description 5
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 5
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
• 241000725303 Human immunodeficiency virus Species 0.000 description 5
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 5
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
• 239000000556 agonist Substances 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 239000012636 effector Substances 0.000 description 5
• 238000002474 experimental method Methods 0.000 description 5
• 230000002209 hydrophobic effect Effects 0.000 description 5
• 230000001939 inductive effect Effects 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 5
• 210000004698 lymphocyte Anatomy 0.000 description 5
• 210000005259 peripheral blood Anatomy 0.000 description 5
• 239000011886 peripheral blood Substances 0.000 description 5
• 229920000747 poly(lactic acid) Polymers 0.000 description 5
• 230000017854 proteolysis Effects 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• 238000012546 transfer Methods 0.000 description 5
• 208000023275 Autoimmune disease Diseases 0.000 description 4
• 208000003174 Brain Neoplasms Diseases 0.000 description 4
• 244000025254 Cannabis sativa Species 0.000 description 4
• 206010009944 Colon cancer Diseases 0.000 description 4
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
• 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 4
• 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 4
• 208000001382 Experimental Melanoma Diseases 0.000 description 4
• 101000917793 Felis catus Major allergen I polypeptide chain 1 Proteins 0.000 description 4
• 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 4
• 108010013476 HLA-A24 Antigen Proteins 0.000 description 4
• 108010058607 HLA-B Antigens Proteins 0.000 description 4
• 206010027476 Metastases Diseases 0.000 description 4
• 102000035195 Peptidases Human genes 0.000 description 4
• 108091005804 Peptidases Proteins 0.000 description 4
• 101000750404 Phoneutria keyserlingi CRISP-1 Proteins 0.000 description 4
• 206010060862 Prostate cancer Diseases 0.000 description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
• 108010076504 Protein Sorting Signals Proteins 0.000 description 4
• 108700019146 Transgenes Proteins 0.000 description 4
• 230000005875 antibody response Effects 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 238000004422 calculation algorithm Methods 0.000 description 4
• 230000032823 cell division Effects 0.000 description 4
• 230000036755 cellular response Effects 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 230000007812 deficiency Effects 0.000 description 4
• 238000003745 diagnosis Methods 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 230000004927 fusion Effects 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 238000001415 gene therapy Methods 0.000 description 4
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
• 239000010931 gold Substances 0.000 description 4
• 229910052737 gold Inorganic materials 0.000 description 4
• 230000006872 improvement Effects 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 230000010354 integration Effects 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 210000001165 lymph node Anatomy 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 238000004806 packaging method and process Methods 0.000 description 4
• 239000004626 polylactic acid Substances 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 229940002612 prodrug Drugs 0.000 description 4
• 239000000651 prodrug Substances 0.000 description 4
• 230000009696 proliferative response Effects 0.000 description 4
• 208000023958 prostate neoplasm Diseases 0.000 description 4
• 230000001681 protective effect Effects 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 230000000638 stimulation Effects 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• 239000003981 vehicle Substances 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
• 206010003402 Arthropod sting Diseases 0.000 description 3
• 206010003645 Atopy Diseases 0.000 description 3
• 206010006187 Breast cancer Diseases 0.000 description 3
• 208000026310 Breast neoplasm Diseases 0.000 description 3
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical class CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
• 108010008629 CA-125 Antigen Proteins 0.000 description 3
• 102000007269 CA-125 Antigen Human genes 0.000 description 3
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
• 229940045513 CTLA4 antagonist Drugs 0.000 description 3
• 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 3
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• 238000011510 Elispot assay Methods 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 108010091938 HLA-B7 Antigen Proteins 0.000 description 3
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
• 206010027480 Metastatic malignant melanoma Diseases 0.000 description 3
• 108010014251 Muramidase Proteins 0.000 description 3
• 102000016943 Muramidase Human genes 0.000 description 3
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
• 102000048850 Neoplasm Genes Human genes 0.000 description 3
• 108700019961 Neoplasm Genes Proteins 0.000 description 3
• 108010033276 Peptide Fragments Proteins 0.000 description 3
• 102000007079 Peptide Fragments Human genes 0.000 description 3
• 239000004365 Protease Substances 0.000 description 3
• 108010016634 Seed Storage Proteins Proteins 0.000 description 3
• 108020004440 Thymidine kinase Proteins 0.000 description 3
• 206010052779 Transplant rejections Diseases 0.000 description 3
• 108020005202 Viral DNA Proteins 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 239000000443 aerosol Substances 0.000 description 3
• 125000001931 aliphatic group Chemical group 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 230000036783 anaphylactic response Effects 0.000 description 3
• 208000003455 anaphylaxis Diseases 0.000 description 3
• 125000000129 anionic group Chemical group 0.000 description 3
• 230000000259 anti-tumor effect Effects 0.000 description 3
• 125000004429 atom Chemical group 0.000 description 3
• 230000001363 autoimmune Effects 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 201000010989 colorectal carcinoma Diseases 0.000 description 3
• 239000006071 cream Substances 0.000 description 3
• 230000003013 cytotoxicity Effects 0.000 description 3
• 231100000135 cytotoxicity Toxicity 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
• 210000000981 epithelium Anatomy 0.000 description 3
• 239000013604 expression vector Substances 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 108010008486 gp100 Melanoma Antigen Proteins 0.000 description 3
• 108010014242 gp100(17-25) peptide Proteins 0.000 description 3
• 230000002998 immunogenetic effect Effects 0.000 description 3
• 230000001506 immunosuppresive effect Effects 0.000 description 3
• 239000012678 infectious agent Substances 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 239000004325 lysozyme Substances 0.000 description 3
• 229960000274 lysozyme Drugs 0.000 description 3
• 235000010335 lysozyme Nutrition 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 210000002752 melanocyte Anatomy 0.000 description 3
• 208000021039 metastatic melanoma Diseases 0.000 description 3
• 206010061289 metastatic neoplasm Diseases 0.000 description 3
• 210000001616 monocyte Anatomy 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 230000000869 mutational effect Effects 0.000 description 3
• 206010028417 myasthenia gravis Diseases 0.000 description 3
• 210000004940 nucleus Anatomy 0.000 description 3
• 235000014571 nuts Nutrition 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 101800002712 p27 Proteins 0.000 description 3
• 230000002093 peripheral effect Effects 0.000 description 3
• 239000000902 placebo Substances 0.000 description 3
• 229940068196 placebo Drugs 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 230000001629 suppression Effects 0.000 description 3
• 238000013268 sustained release Methods 0.000 description 3
• 239000012730 sustained-release form Substances 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 238000010361 transduction Methods 0.000 description 3
• 230000026683 transduction Effects 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• 230000032258 transport Effects 0.000 description 3
• 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 206010002198 Anaphylactic reaction Diseases 0.000 description 2
• 102100030346 Antigen peptide transporter 1 Human genes 0.000 description 2
• 102100030343 Antigen peptide transporter 2 Human genes 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• 241000238657 Blattella germanica Species 0.000 description 2
• 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 101710132601 Capsid protein Proteins 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 150000008574 D-amino acids Chemical class 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• 241000702421 Dependoparvovirus Species 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 101710091045 Envelope protein Proteins 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 description 2
• 102220378376 HLA-B*2705 Human genes 0.000 description 2
• 108010054198 HLA-B*27:05 antigen Proteins 0.000 description 2
• 108010086786 HLA-DQA1 antigen Proteins 0.000 description 2
• 241000700721 Hepatitis B virus Species 0.000 description 2
• 101100382122 Homo sapiens CIITA gene Proteins 0.000 description 2
• 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 2
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
• 206010062016 Immunosuppression Diseases 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 102100034349 Integrase Human genes 0.000 description 2
• 102000008070 Interferon-gamma Human genes 0.000 description 2
• 206010022998 Irritability Diseases 0.000 description 2
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
• 240000007472 Leucaena leucocephala Species 0.000 description 2
• 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
• 241000209082 Lolium Species 0.000 description 2
• 240000004296 Lolium perenne Species 0.000 description 2
• 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
• 241000702623 Minute virus of mice Species 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 229920001710 Polyorthoester Polymers 0.000 description 2
• 101710188315 Protein X Proteins 0.000 description 2
• 241001068263 Replication competent viruses Species 0.000 description 2
• 241000607142 Salmonella Species 0.000 description 2
• 244000082988 Secale cereale Species 0.000 description 2
• 235000007238 Secale cereale Nutrition 0.000 description 2
• 241000700584 Simplexvirus Species 0.000 description 2
• 208000001203 Smallpox Diseases 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
• 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 description 2
• 102000006601 Thymidine Kinase Human genes 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• 241000870995 Variola Species 0.000 description 2
• 241000700647 Variola virus Species 0.000 description 2
• 108700005077 Viral Genes Proteins 0.000 description 2
• 230000021736 acetylation Effects 0.000 description 2
• 238000006640 acetylation reaction Methods 0.000 description 2
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
• 230000009435 amidation Effects 0.000 description 2
• 238000007112 amidation reaction Methods 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000002238 attenuated effect Effects 0.000 description 2
• 230000005784 autoimmunity Effects 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000008827 biological function Effects 0.000 description 2
• 238000010170 biological method Methods 0.000 description 2
• 230000008512 biological response Effects 0.000 description 2
• 239000013575 birch pollen allergen Substances 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 230000000139 costimulatory effect Effects 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 230000002939 deleterious effect Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 230000006806 disease prevention Effects 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 238000006073 displacement reaction Methods 0.000 description 2
• 238000010494 dissociation reaction Methods 0.000 description 2
• 230000005593 dissociations Effects 0.000 description 2
• 239000002359 drug metabolite Substances 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 108700004025 env Genes Proteins 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 210000003979 eosinophil Anatomy 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 108700004026 gag Genes Proteins 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 108010072094 gp100(280-288) melanoma antigen peptide Proteins 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• 239000000833 heterodimer Substances 0.000 description 2
• 210000003630 histaminocyte Anatomy 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 230000001024 immunotherapeutic effect Effects 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 230000017307 interleukin-4 production Effects 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 230000002147 killing effect Effects 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 235000010981 methylcellulose Nutrition 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 210000001539 phagocyte Anatomy 0.000 description 2
• 239000008194 pharmaceutical composition Substances 0.000 description 2
• 210000004180 plasmocyte Anatomy 0.000 description 2
• 229920001610 polycaprolactone Polymers 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 235000019419 proteases Nutrition 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 230000006798 recombination Effects 0.000 description 2
• 238000005215 recombination Methods 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000003362 replicative effect Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 238000001338 self-assembly Methods 0.000 description 2
• 239000002453 shampoo Substances 0.000 description 2
• 239000012453 solvate Substances 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 230000007480 spreading Effects 0.000 description 2
• 238000003892 spreading Methods 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 229960000814 tetanus toxoid Drugs 0.000 description 2
• 239000012049 topical pharmaceutical composition Substances 0.000 description 2
• 235000010487 tragacanth Nutrition 0.000 description 2
• 239000000196 tragacanth Substances 0.000 description 2
• 229940116362 tragacanth Drugs 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 230000002463 transducing effect Effects 0.000 description 2
• 238000011830 transgenic mouse model Methods 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• 241000712461 unidentified influenza virus Species 0.000 description 2
• 230000029812 viral genome replication Effects 0.000 description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
• GHPCICSQWQDZLM-UHFFFAOYSA-N 1-(4-chlorophenyl)sulfonyl-1-methyl-3-propylurea Chemical compound CCCNC(=O)N(C)S(=O)(=O)C1=CC=C(Cl)C=C1 GHPCICSQWQDZLM-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• ZENKESXKWBIZCV-UHFFFAOYSA-N 2,2,4,4-tetrafluoro-1,3-benzodioxin-6-amine Chemical group O1C(F)(F)OC(F)(F)C2=CC(N)=CC=C21 ZENKESXKWBIZCV-UHFFFAOYSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 206010001742 Allergy to animal Diseases 0.000 description 1
• 244000144927 Aloe barbadensis Species 0.000 description 1
• 235000002961 Aloe barbadensis Nutrition 0.000 description 1
• 208000033399 Anaphylactic responses Diseases 0.000 description 1
• 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
• 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
• 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
• 238000011725 BALB/c mouse Methods 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• 238000011740 C57BL/6 mouse Methods 0.000 description 1
• 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
• 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
• 102100036008 CD48 antigen Human genes 0.000 description 1
• 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
• 108090000565 Capsid Proteins Proteins 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 101710190849 Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 102000005600 Cathepsins Human genes 0.000 description 1
• 108010084457 Cathepsins Proteins 0.000 description 1
• 241000736839 Chara Species 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• 108091062157 Cis-regulatory element Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
• 101710094648 Coat protein Proteins 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 241000450599 DNA viruses Species 0.000 description 1
• 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
• 241000521299 Deinocerites cancer Species 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 101150029662 E1 gene Proteins 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 241001115402 Ebolavirus Species 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 241000701867 Enterobacteria phage T7 Species 0.000 description 1
• 206010014950 Eosinophilia Diseases 0.000 description 1
• 241001331845 Equus asinus x caballus Species 0.000 description 1
• 101100377706 Escherichia phage T5 A2.2 gene Proteins 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 108700013752 Felis domesticus Fel d 1 Proteins 0.000 description 1
• 101710145505 Fiber protein Proteins 0.000 description 1
• 208000000666 Fowlpox Diseases 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
• 102100031618 HLA class II histocompatibility antigen, DP beta 1 chain Human genes 0.000 description 1
• 108010036972 HLA-A11 Antigen Proteins 0.000 description 1
• 102220391613 HLA-B*2702 Human genes 0.000 description 1
• 108010037618 HLA-C*08 antigen Proteins 0.000 description 1
• 108010045483 HLA-DPB1 antigen Proteins 0.000 description 1
• 108010046732 HLA-DR4 Antigen Proteins 0.000 description 1
• 108010061311 HLA-DRB3 Chains Proteins 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
• 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
• 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 1
• 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 1
• 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
• 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 1
• 101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 1
• 101000796203 Homo sapiens L-dopachrome tautomerase Proteins 0.000 description 1
• 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 1
• 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
• 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
• 108090000176 Interleukin-13 Proteins 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 102100026371 MHC class II transactivator Human genes 0.000 description 1
• 108700002010 MHC class II transactivator Proteins 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 101710125418 Major capsid protein Proteins 0.000 description 1
• 206010064912 Malignant transformation Diseases 0.000 description 1
• 108010031099 Mannose Receptor Proteins 0.000 description 1
• 241001115401 Marburgvirus Species 0.000 description 1
• 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
• 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
• 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 241000714177 Murine leukemia virus Species 0.000 description 1
• 241000186359 Mycobacterium Species 0.000 description 1
• 241000204031 Mycoplasma Species 0.000 description 1
• ONXPDKGXOOORHB-BYPYZUCNSA-N N(5)-methyl-L-glutamine Chemical compound CNC(=O)CC[C@H](N)C(O)=O ONXPDKGXOOORHB-BYPYZUCNSA-N 0.000 description 1
• 230000004988 N-glycosylation Effects 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 101710141454 Nucleoprotein Proteins 0.000 description 1
• REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 108010058846 Ovalbumin Proteins 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 101000963862 Phleum pratense Pollen allergen Phl p 1 Proteins 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 241001337451 Polyblastus cancer Species 0.000 description 1
• 229920001273 Polyhydroxy acid Polymers 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 229940124939 Pox vaccine Drugs 0.000 description 1
• 101710083689 Probable capsid protein Proteins 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 101710194807 Protective antigen Proteins 0.000 description 1
• 241000125945 Protoparvovirus Species 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 230000010799 Receptor Interactions Effects 0.000 description 1
• 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
• 241001068295 Replication defective viruses Species 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 241000606701 Rickettsia Species 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 206010040825 Skin depigmentation Diseases 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 229930182558 Sterol Natural products 0.000 description 1
• 101710172711 Structural protein Proteins 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 108010008038 Synthetic Vaccines Proteins 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 230000017274 T cell anergy Effects 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
• 101710137500 T7 RNA polymerase Proteins 0.000 description 1
• 101150052863 THY1 gene Proteins 0.000 description 1
• 101710192266 Tegument protein VP22 Proteins 0.000 description 1
• 108010055044 Tetanus Toxin Proteins 0.000 description 1
• 206010044248 Toxic shock syndrome Diseases 0.000 description 1
• 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 101710196023 Vicilin Proteins 0.000 description 1
• 108010067390 Viral Proteins Proteins 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 238000002441 X-ray diffraction Methods 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 102100026497 Zinc finger protein 654 Human genes 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 231100000230 acceptable toxicity Toxicity 0.000 description 1
• 150000008043 acidic salts Chemical class 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 230000009824 affinity maturation Effects 0.000 description 1
• 208000037883 airway inflammation Diseases 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 125000003158 alcohol group Chemical group 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000003973 alkyl amines Chemical class 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 125000005233 alkylalcohol group Chemical group 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 108010016737 allergen Ara h3 Proteins 0.000 description 1
• 230000002009 allergenic effect Effects 0.000 description 1
• 230000009285 allergic inflammation Effects 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 235000011399 aloe vera Nutrition 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 229960000510 ammonia Drugs 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 230000002052 anaphylactic effect Effects 0.000 description 1
• 210000003484 anatomy Anatomy 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000002223 anti-pathogen Effects 0.000 description 1
• 230000005809 anti-tumor immunity Effects 0.000 description 1
• 230000006023 anti-tumor response Effects 0.000 description 1
• 230000005975 antitumor immune response Effects 0.000 description 1
• 238000003491 array Methods 0.000 description 1
• 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
• 229940065181 bacillus anthracis Drugs 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• ZYXYTGQFPZEUFX-UHFFFAOYSA-N benzpyrimoxan Chemical compound O1C(OCCC1)C=1C(=NC=NC=1)OCC1=CC=C(C=C1)C(F)(F)F ZYXYTGQFPZEUFX-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• MBGOSTCRFOFESL-UHFFFAOYSA-N butane-1,4-diamine hydrate Chemical compound O.NCCCCN MBGOSTCRFOFESL-UHFFFAOYSA-N 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 210000000234 capsid Anatomy 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 229940105329 carboxymethylcellulose Drugs 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 229940030156 cell vaccine Drugs 0.000 description 1
• 230000007969 cellular immunity Effects 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 229940090805 clavulanate Drugs 0.000 description 1
• HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 238000000205 computational method Methods 0.000 description 1
• 230000002153 concerted effect Effects 0.000 description 1
• 239000004020 conductor Substances 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000037029 cross reaction Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 210000000172 cytosol Anatomy 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000007402 cytotoxic response Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000000326 densiometry Methods 0.000 description 1
• 238000009795 derivation Methods 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
• 239000001177 diphosphate Substances 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
• 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 229940009662 edetate Drugs 0.000 description 1
• 230000005684 electric field Effects 0.000 description 1
• 238000010892 electric spark Methods 0.000 description 1
• 230000009881 electrostatic interaction Effects 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 231100000655 enterotoxin Toxicity 0.000 description 1
• 238000003920 environmental process Methods 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 229950000206 estolate Drugs 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 101150098622 gag gene Proteins 0.000 description 1
• 229940044627 gamma-interferon Drugs 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 229940046528 grass pollen Drugs 0.000 description 1
• 239000013574 grass pollen allergen Substances 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 108010021083 hen egg lysozyme Proteins 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 230000005745 host immune response Effects 0.000 description 1
• 102000007579 human kallikrein-related peptidase 3 Human genes 0.000 description 1
• 108010071652 human kallikrein-related peptidase 3 Proteins 0.000 description 1
• 230000028996 humoral immune response Effects 0.000 description 1
• 210000004408 hybridoma Anatomy 0.000 description 1
• XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 150000002433 hydrophilic molecules Chemical class 0.000 description 1
• 230000004047 hyperresponsiveness Effects 0.000 description 1
• 230000004046 hyporesponsiveness Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000006054 immunological memory Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 230000031261 interleukin-10 production Effects 0.000 description 1
• 229940028885 interleukin-4 Drugs 0.000 description 1
• 230000022023 interleukin-5 production Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 230000000622 irritating effect Effects 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 229940099584 lactobionate Drugs 0.000 description 1
• JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
• 229940070765 laurate Drugs 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 230000002101 lytic effect Effects 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 230000036212 malign transformation Effects 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 230000005741 malignant process Effects 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 230000015654 memory Effects 0.000 description 1
• 210000003071 memory t lymphocyte Anatomy 0.000 description 1
• 230000004066 metabolic change Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
• 229940102396 methyl bromide Drugs 0.000 description 1
• LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
• JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 230000003228 microsomal effect Effects 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 108091005601 modified peptides Proteins 0.000 description 1
• 102000035118 modified proteins Human genes 0.000 description 1
• 108091005573 modified proteins Proteins 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 238000000302 molecular modelling Methods 0.000 description 1
• 229940078555 myristyl propionate Drugs 0.000 description 1
• 210000004897 n-terminal region Anatomy 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 238000003305 oral gavage Methods 0.000 description 1
• 239000007935 oral tablet Substances 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 229940092253 ovalbumin Drugs 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 238000007427 paired t-test Methods 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 229940014662 pantothenate Drugs 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 239000011713 pantothenic acid Substances 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 230000003071 parasitic effect Effects 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 102000014187 peptide receptors Human genes 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 150000008105 phosphatidylcholines Chemical class 0.000 description 1
• 201000009442 piebaldism Diseases 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 108700004029 pol Genes Proteins 0.000 description 1
• 239000013573 pollen allergen Substances 0.000 description 1
• 229920002627 poly(phosphazenes) Polymers 0.000 description 1
• 229920002721 polycyanoacrylate Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 229920006324 polyoxymethylene Polymers 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229940124606 potential therapeutic agent Drugs 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 229940024231 poxvirus vaccine Drugs 0.000 description 1
• 238000009021 pre-vaccination Methods 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 230000001566 pro-viral effect Effects 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 210000005267 prostate cell Anatomy 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 238000003908 quality control method Methods 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 210000003289 regulatory T cell Anatomy 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000003307 reticuloendothelial effect Effects 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 238000013515 script Methods 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000015424 sodium Nutrition 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 230000003393 splenic effect Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 150000003432 sterols Chemical class 0.000 description 1
• 235000003702 sterols Nutrition 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 230000002483 superagonistic effect Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 238000011191 terminal modification Methods 0.000 description 1
• 229940118376 tetanus toxin Drugs 0.000 description 1
• YRZGMTHQPGNLEK-UHFFFAOYSA-N tetradecyl propionate Chemical compound CCCCCCCCCCCCCCOC(=O)CC YRZGMTHQPGNLEK-UHFFFAOYSA-N 0.000 description 1
• 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 230000001810 trypsinlike Effects 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 239000002691 unilamellar liposome Substances 0.000 description 1
• 108700000403 vaccinia-CEA vaccine Proteins 0.000 description 1
• 229940070710 valerate Drugs 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 235000019155 vitamin A Nutrition 0.000 description 1
• 239000011719 vitamin A Substances 0.000 description 1
• 235000019165 vitamin E Nutrition 0.000 description 1
• 239000011709 vitamin E Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229930195724 β-lactose Natural products 0.000 description 1